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ABSTRACT
We demonstrated previously that tumor lysate–pulsed dendritic cells (TP-DC) could mediate a specific and
long-lasting antitumor immune response against a weakly immunogenic breast tumor during early lymphoid
reconstitution. The purpose of this study was to examine the potential therapeutic efficacy of bone marrow
transplants from TP-DC–vaccinated donors. In 2 aggressive metastatic models, bone marrow transplantation
with donor bone marrow cells from TP-DC–immunized mice mediated a tumor-specific immune response in
the recipient, and this caused regressions of preexisting tumor metastases. After vaccination with TP-DC,
donors harbored increased numbers of both activated CD4 and CD8 T-cell populations in the bone marrow.
Adoptive transfer of T cells purified from the bone marrow of TP-DC–vaccinated mice led to a reduction in
preestablished lung metastases, whereas depletion of T cells from bone marrow abolished this effect. By using
T cells derived from the bone marrow of TP-DC–vaccinated major histocompatibility complex class I and class
II knockout mice, the effector cells required for the observed antitumor effect were determined to be major
histocompatibility complex class I–restricted CD8 T cells. Additionally, the tumor burden in TP-DC–
immunized transplant recipients could be reduced further by repetitive TP-DC immunizations after bone
marrow transplantation. Collectively, these results demonstrate an important therapeutic role of bone marrow
from TP-DC–immunized donors and raise the potential for this approach in patients with advanced cancer.
© 2004 American Society for Blood and Marrow Transplantation
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iNTRODUCTION
Bone marrow transplantation (BMT) has been
idely used in the clinical setting as one form of
herapy for malignancy. Although antitumor activity
fter allogeneic BMT can be signiﬁcant because of a
raft-versus-tumor (GVT) effect, the prognosis is
enerally poor, especially in patients with acute leu-
emia, in whom treatment-related morbidity, relapse
ate, and mortality are high [1-7]. Autologous BMT
voids the risks associated with graft-versus-host dis-
ase; however, tumor recurrence is problematic,
ainly because of the absence of a GVT effect. Sev- a
24ral investigators have demonstrated the successful
ransfer of antigen-speciﬁc immunity from an immu-
ized donor to a recipient in both humans [8-11] and
nimals [12-22]. For example, transfer of tumor idio-
ype-speciﬁc immunity from the bone marrow (BM)
f donor mice previously immunized with tumor-de-
ived surface immunoglobulin protein could mediate
rotection against lethal syngeneic tumor challenge in
he recipient [14]. Feuerer et al. [19] demonstrated
hat tumor-speciﬁc memory T cells in the BM of
reast cancer patients could be adoptively transferred
nto NOD/SCID mice and mediated a regression of
utologous tumor xenotransplants. Other studies by
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Augmentation of Antitumor Immune Responses
Bwak et al. [12] showed that a speciﬁc T-cell immu-
ity against a deﬁned tumor antigen could be trans-
erred from the donor to a syngeneic tumor-bearing
ecipient. Transplantation of BM-derived stem cells
ransduced with a deﬁned tumor antigen has led to
xpansion and activation of tumor-speciﬁc T cells
23]. Although these ﬁndings are encouraging to the
eld of adoptive immunotherapy of cancer, the oppor-
unity exists for further improvement by additional
herapeutic strategies.
Recent attempts to improve immunotherapy of
ancer have included the use of dendritic cells (DCs)
n tumor vaccine approaches. DCs are antigen-pre-
enting cells of BM origin and are recognized as po-
ent initiators of immune responses. Our group [24-
6] and others [27-32] have documented the capacity
f tumor lysate–pulsed DCs (TP-DCs) to elicit potent
ntitumor T-cell responses in immunocompetent
osts. Recently, we have also shown that TP-DCs
ould prime a speciﬁc and long-lasting antitumor im-
une response during early lymphoid reconstitution
fter BMT [33].
It has been proposed that 2 pathways are involved
n the regeneration of the T-cell repertoire in recipi-
nts after intensive chemotherapy treatment or lethal
adiation followed by BMT [34]. First, the thymic-
ependent pathway involves new T cells generated
rom T-cell progenitors via thymopoiesis [35,36]. The
ew T-cell repertoire would display naive-type surface
arkers, which resemble cells in young hosts [36].
econd, in the absence of thymus, T-cell regeneration
nvolves extensive peripheral expansion of mature T
ells [37-39]. Thus, T-cell repertoire diversity gener-
ted from this thymic-independent pathway is limited
y the diversity of T cells contained in the BM given
s the transplant [40]. Here, we attempted to modu-
ate the antitumor immunity in BMT recipients by the
doptive transfer of BM from donor mice that were
mmunized with TP-DC. We hypothesized that BM
f the TP-DC–immunized mice would contain tu-
or-reactive, mature immune T cells that, when
doptively transferred to the recipients, could success-
ully transfer the antitumor immunity as well. To
urther understand the contribution of T cells found
n BMT to antitumor immunity, T cells puriﬁed from
he BM of wild-type (WT), major histocompatibility
omplex (MHC) class I and II knockout (KO) mice
ere used to treat preestablished lung metastases in
mmunocompetent mice.
ATERIALS AND METHODS
nimals and Tumors
Six- to 8-week-old female BALB/c mice were pur-
hased from the Jackson Laboratory (Bar Harbor,
E). Six- to 8-week old female C57BL/6 mice were w
B&MTurchased from Harlan Laboratories (Indianapolis,
N). MHC class I and II KO mice (both on a
57BL/6 background) were purchased from Taconic
arm (Indianapolis, IN). Mice were housed at the
nimal Research Facility of the University of Michi-
an Medical Center. The animals were used between
and 12 weeks of age. The weakly immunogenic
T-901 tumor was derived from an early in vivo
assage of a cultured MT-7 dimethylbenzanthracene-
nduced mammary carcinoma in the BALB/c strain
41]. The A20 B-cell lymphoma was derived from a
pontaneous reticulum cell neoplasm that developed
n an aged BALB/c mouse [42]. The B16-BL6 mela-
oma was a tumor of spontaneous origin in C57BL/6
ice.
eneration of TP-DC
BM cells were harvested from ﬂushed marrow
avities of femurs and tibiae of mice under aseptic
onditions and were cultured in complete medium
CM) supplemented with granulocyte-macrophage
olony-stimulating factor 10 ng/mL and interleukin-4
0 ng/mL at 1  106 cells per milliliter. DCs were
arvested from day 4 cultures, washed, and resus-
ended at 5  106 cells per milliliter. The population
as enriched by 14.5% (by weight) metrizamide CM
ensity gradient separation. After centrifugation (15
inutes at 4°C; 2000 rpm), the DCs (90% purity)
ere collected from the low-density interface and
ashed twice in CM. Viable tumor cells were sus-
ended at 1  107 cells per milliliter in CM. After 4
ycles of rapid freeze (160°C) and thaw (37°C), the
umor cell suspension was then centrifuged at low
peed (400 rpm for 10 minutes). The supernatant
tumor lysate) was collected and incubated with puri-
ed DCs overnight at a ratio of 3:1 tumor cell equiv-
lents to DCs. TP-DC were harvested and washed 3
imes in Hanks balanced salt solution (HBSS) for
urther studies.
eneration of Immune BM Cells (DC-BM)
Naive mice received 2 or 3 immunizations of
P-DC via subcutaneous injection, 2  106 TP-DCs
er immunization, 4 to 7 days apart. Whole BM cells
ere harvested 4 to 7 days after the last vaccination,
ashed 3 times, and resuspended in HBSS at 2  107
ells per milliliter. BM cells were harvested from fe-
urs and tibiae of syngeneic age-matched donor mice
s described previously [33].
yngeneic BMT
A lethal dose of total body irradiation (TBI; 950
Gy) was administered to mice via a cesium 137
amma-irradiation source (Gamma Cell 40; Nordion
nternational Inc., Kanata, Ontario, Canada). Mice
5 5ere challenged with 2 10 B16 or 4 10 MT-901
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5ells. Seven days later, mice (n 5 per group) received
BI and an infusion of 1  107 naive BM or DC-BM
ells via tail vein injection in 0.5 mL of HBSS. Alter-
atively, BALB/c mice received TBI, and 1 day later,
ice (n  10 per group) received an infusion of 2 
04 MT-901 cells admixed with either naive BM or
C-BM via tail vein injection in 0.5 mL of HBSS.
epletion of T Cells from DC-BM
T cells were depleted from DC-BM by negative
election with either anti-CD90 (Thy 1.2) or anti-
D4 and anti-CD8 magnetic beads (Miltenyi Biotec
nc., Auburn, CA). The efﬂuent cells were passed
hrough the magnetic column twice to increase the
urity of T cell–depleted BM cells. After depletion of
cells, DC-BM were washed 4 times with HBSS and
esuspended for further studies. The purity of the T
ell–depleted DC-BM was determined by using a
-color monoclonal antibody panel of ﬂuorescein iso-
hiocyanate–conjugated anti-CD4, phycoerythrin-
onjugated anti-CD8, and appropriate isotype-
atched controls (BD PharMingen, San Diego, CA)
o stain the appropriate cell-surface markers. Analysis
as performed by ﬂow cytometry (FACScan; BD Im-
unocytometry Systems, San Jose, CA).
urification of T Cells from BM
Erythrocyte-depleted BM cells ﬂushed from the
emurs and tibiae of B6 mice were suspended in phos-
hate-buffered saline supplemented with ethylenedia-
inetetraacetic acid (2 mmol/L) at 107 cells per 90
L. Cells were stained with 10 g of anti-CD90
agnetic beads for 20 minutes on ice. After 3 washes,
cells were puriﬁed by a MACS separation column
Miltenyi Biotec, Inc.). The purity of CD3 cells was
80% (data not shown).
roliferation Assay
BM cells from naive (n  5) or TP-DC–immu-
ized (n  5) recipient mice (3 immunizations of
2  106 cells, each given 4 days apart) were har-
ested 7 days after the last immunization and were
ncubated in 96-well U-bottom microtiter plates at
 105 cells per well at 37°C for 3 days. BM cells
ere cocultured with 1  105 stimulator cells, which
ncluded irradiated MT-901 mammary carcinoma
20000 cGy) and A20 B-cell lymphoma (30000 cGy).
n day 2, the cells were pulsed with [3H]thymidine 1
Ci/mL (NEN Life Science Products Inc., Boston,
A) and were harvested 24 hours later. Proliferative
esponses were reported as mean counts per minute
cpm)  SEM for each group, which consisted of 6
eplicate wells per mouse. m
26nzyme-Linked Immunosorbent Assay
CD90 puriﬁed T cells from the BM of naive or
P-DC–immunized mice were harvested, and 1 
05 cells were cultured alone or with 1  105 B16
elanoma or EL-4 cells for 48 hours. Supernatants
ere harvested, and interferon (IFN)- was measured
ccording to the manufacturer’s protocol (PharMin-
en).
reatment of Lung Metastases with T Cells
urified from BM
C57BL/6 mice were challenged with 1  105
16-BL6 cells. Three days later, mice (n  5 per
roup) were treated intravenously with either HBSS
r 5  106 T cells puriﬁed from DC-BM generated in
T C57BL/6, MHC class I KO, or MHC class II
O mice. Lungs were harvested on day 14, and the
umber of lung metastases was counted.
ost-BMT Immunization
After TBI and syngeneic BMT, recipient mice
ere immunized with 1 106 TP-DC subcutaneously
n days 7, 11, and 15.
tatistical Analysis
A Mann-Whitney test (unpaired) or a paired t test
as used to compare treatment groups. A nonpara-
etric 1-way analysis of variance was performed (fol-
owed by a Dunn multiple comparison posttest) to
ompare the number of lung metastases between
roups. All statistical evaluations were performed with
raphPad Prism (GraphPad Software, San Diego,
A). Statistical signiﬁcance was achieved at P 	 .05.
ESULTS
uccessful Adoptive Transfer of Antitumor
mmunity in DC-BM–Transplanted Recipients
In a mouse model of metastatic breast cancer, we
valuated the efﬁcacy of various BMT treatment reg-
mens. One day after a lethal dose of TBI, BALB/c
ice (n  10 per group) received 2  104 MT-901
ells admixed with whole BM cells derived from TP-
C–immunized mice (DC-BM) or whole BM from
aive donors (nBM). DC-BM donor mice received 2
ubcutaneous injections of MT-901 TP-DC 2 times at
-day intervals. As shown in Figure 1A, the number of
esidual pulmonary metastases in DC-BM–trans-
lanted mice (64  6) was reduced by approximately
0% of that in mice transplanted with normal BM
ells (nBM; 134  22; P 	 .001). Without BMT, all
BI mice died within 10 days from the lethal effects of
BI (data not shown).
Next, we tested BMT in a metastatic melanomaodel in C57BL/6 mice. Seven days after injection of
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Augmentation of Antitumor Immune Responses
B 105 B16-BL6 cells, mice received a lethal dose of
BI and were treated with 1  107 BM cells. These
ells were obtained from either naive donors or mice
hat had been vaccinated 2 times with B16 TP-DC. At
ay 14 after tumor challenge, lung metastases were
easured. Similar to the BALB/c model, C57BL/6
ice that had received DC-BM had a signiﬁcant re-
uction in tumor (125  11) compared with mice that
eceived nBM (229  13; P 	 .001; Figure 1B). In the
bsence of BMT, mice died within 10 days and had
ore than 300 lung metastases (data not shown).
henotypic Differences between DC-BM and
aive BM
We determined the phenotype of DC-BM com-
ared with normal BM by ﬂuorescence-activated cell
orting analysis (Figure 2). Naive BM contained a low
ercentage of mature T cells, of which 5.1%  0.9%
ere CD4 and 1.2%  0.1% were CD8 (mean 
EM from 4 independent experiments). In contrast,
he percentages of CD4 and CD8T cells were both
ncreased in DC-BM (11.2%  1.0% and 3.0% 
.4% for CD4 and CD8 cells [mean  SEM from
independent experiments consisting of 5 mice per
roup], respectively; P 	 .02 for comparison of
CD4 cells of nBM versus DC-BM and of %CD8
ells of nBM versus DC-BM by Mann-Whitney test).
ther antibodies to cell-surface markers were also
sed, including anti-DX5 (for natural killer cells), an-
i-CD19, and anti-B220 (both for B cells); however,
o difference between normal BM and DC-BM was
etected (data not shown). CD3CD4CD8 cells
igure 1. Adoptive transfer of antitumor immunity by TP-DC–
mmunized donor BM transplanted into recipient mice. A, One day
fter TBI, BALB/c mice received either 1  107 BM cells (nBM) or
M from TP-DC–immunized mice (DC-BM) with 2  104 viable
T-901 cells intravenously. Lungs were harvested 2 weeks later.
hown here is a representative of 3 similar experiments in which 10
ice were used per treatment group. (B) C57BL/6 mice were
hallenged intravenously with 2  105 B16-BL6. Seven days later,
ice received TBI followed by 1  107 nBM or TP-DC. Lungs
ere harvested 2 weeks later. Data are reported as average lung
etastases  SEM from 5 mice per group. *P 	 .001.ere detected both in nBM and DC-BM, with the
B&MTatter showing an increased level compared with the
ormer (P 	 .003 by Mann-Whitney test).
Cells in DC-BM Express Activation Markers
Because both CD4 and CD8 T cells were in-
reased in BM after TP-DC immunization, we exam-
ned whether there were any differences in the phe-
otype of these cells in comparison to nBM. T cells in
M were enriched by anti-CD90 MACS beads, and
henotypes were examined by ﬂuorescence-activated
ell sorting analysis. As shown in Table 1, increased
xpression of the activation markers CD69 and CD25,
s well as decreased expression of CD62L, was mea-
ured in CD4/CD8 T-cell populations in DC-BM
ompared with nBM.
umor-Specific Reactivity of T Cells in DC-BM
To characterize the antitumor activity of DC-BM,
e next examined its tumor-speciﬁc proliferative ca-
igure 2. Phenotypic comparison of naive BM and DC-BM. Naive
ALB/c mice (n 5) were immunized subcutaneously with 2 106
P-DC cells twice, 4 days apart. Five days later, DC-BM was
arvested, and T cell–surface markers were analyzed by ﬂuores-
ence-activated cell sorting analysis. Data are reported as mean 
EM from 5 independent experiments, each containing 5 mice per
roup.
able 1. T Cells in Bone Marrow Express Activation Markers
Group (n  5)
CD4/CD8 Positive
CD25 CD69 CD62L
M-DC 7.4% 23% 14%
m.SP 4.8% 4.8% 6.8%
BM 4.8% 4.8% 6.8%527
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5acity in vitro. As shown in Figure 3, DC-BM derived
rom mice vaccinated with MT-901 TP-DC prolifer-
ted to some extent in the absence of stimulator cells
2196  1601 cpm), as did irradiated MT-901
2768 288) and A20 (1260 261) cells alone. Naive
M cells (nBM) minimally proliferated after 3 days in
M (210  50). The proliferation of DC-BM cells
as signiﬁcantly increased when stimulated with irra-
iated MT-901, but not with the irrelevant irradiated
20 tumor cells (10698  2575 versus 3515  797
pm, respectively; P 	 .01).
Cells in DC-BM Secrete IFN- in an
ntigen-Specific Manner
To determine the functionality of T cells from
C-BM derived from mice vaccinated with B16 TP-
C, puriﬁed T cells were cocultured alone or with
16-BL6 or irrelevant EL-4 tumor for 48 hours. Cul-
ure supernatants were harvested, and IFN- was
easured in a standard enzyme-linked immunosor-
ent assay. As shown in Figure 4, high amounts of
FN- were generated by T cells from DC-BM in
esponse to B16 (2386  412 pg/mL) but not EL-4
848  101 pg/mL) tumors. No detectable IFN- was
enerated by T cells from naive BM.
he In Vivo Antitumor Activity of DC-BM is T-Cell
ediated
To further characterize the antitumor activity of
C-BM, we next determined whether the antitumor
igure 3. Tumor-speciﬁc proliferative responsiveness of DC-BM.
C-BM cells were harvested and used as responder cells as de-
cribed in Materials and Methods. DC-BM (1  105 cells) were
o-cultured with either 1  105 irradiated MT-901 or A20 stimu-
ator cells. Comparison was also made with DC-BM, nBM, MT-
01, and A20 cells alone. Proliferation was measured after 3 days of
oculture. Data are reported as mean  SEM from 3 independent
xperiments, each containing 5 mice per group. *P 	 .01 compared
ith DC-BM  A20. v
28mmune response of transplanted DC-BM in vivo was
ependent on T cells in the BMT. As shown in Figure
A, adoptive transfer of DC-BM resulted in a signif-
cant reduction in the number of lung metastases
DC-BM, 88  19; nBM, 170  12; P 	 .001). When
epleted of T cells with anti-CD90 microbeads, how-
igure 4. T cells in DC-BM secrete IFN- in a tumor-speciﬁc
anner. C57BL/6 mice (n  5) received 1  106 B16 lysate–pulsed
Cs subcutaneously 2 times at 4-day intervals. Four days later, BM
as harvested, and T cells were enriched by MACS sorting. T cells
1 105) were cocultured with CM, 1 105 irradiated B16-BL6, or
L-4 cells for 48 hours. Supernatants were harvested, and IFN-
as measured in a standard enzyme-linked immunosorbent assay.
aive T cells puriﬁed from BM (n  5) were used as a negative
ontrol. ND indicates not detectable.
igure 5. The in vivo antitumor effect of DC-BM is T-cell medi-
ted. A, Naive BALB/c mice received 4  105 MT-901 cells intra-
enously 7 days before TBI and BMT. DC-BM cells were harvested
rom donor mice 7 days after 2 TP-DC immunizations. TBI recip-
ent mice (n  5 per group) received 1  107 syngeneic BM from
aive mice (nBM), DC-BM, or T cell–depleted DC-BM. Lungs
ere harvested 3 weeks later. *P 	 .001 for comparison of DC-BM
ersus T cell–depleted DC-BM and of DC-BM versus nBM. B,
57BL/6 mice received 2  105 viable B16-BL6 cells intravenously
days before TBI. On day 7, mice (n  5 per group) received 8 
06 T cell–depleted DC-BM admixed with either 2  106 naive T
ells or 2  106 T cells puriﬁed from DC-BM. Lungs were har-
ested 14 days later. **P 	 .01.
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Augmentation of Antitumor Immune Responses
Bver, DC-BM failed to elicit an antitumor effect (T
ell–depleted DC-BM: 150  10).
To verify that T cells in the BMT mediated the
ntitumor effect, we exchanged T cells between naive
M and DC-BM. To generate DC-BM, mice re-
eived 2 TP-DC immunizations 4 days apart. On day
after the ﬁnal vaccination, BM was harvested. CD4
nd CD8 T cells were depleted as described in Ma-
erials and Methods. We then admixed the T cell–
epleted DC-BM with T cells puriﬁed from either
aive BM or DC-BM. As shown in Figure 5B, only
ice that received DC-BM reconstituted with T cells
erived from DC-BM had a reduction in the number
f lung metastases (59  17). This was a signiﬁcant
eduction (P 	 .01) compared with mice that received
C-BM reconstituted with T cells derived from naive
M (160  37).
HC Class I–Restricted T Cells in DC-BM Are the
redominant Antitumor Effectors In Vivo
To determine the T-cell effector population in
C-BM, C57BL/6 mice were challenged with 1 
05 viable B16-BL6 cells. Three days later, mice were
reated with either HBSS or 5  106 T cells puriﬁed
rom DC-BM. DC-BM were generated in C57BL/6
WT), MHC class I KO (I KO), or MHC class II KO
II KO) mice. DCs derived from MHC class I and II
O mice expressed the same levels of co-stimulatory
olecules such as CD40, CD80, and CD86 as DCs
erived from WT mice. DC populations from each
ouse strain contained 80% CD40, 95%
D80, and 70% CD86 cells (data not shown). In
HC class I KO mice, 90% of DCs expressed
HC class II, and	1% of DCs expressed MHC class
igure 6. MHC class I–restricted T cells in DC-BM are the
redominant antitumor effectors in vivo. C57BL/6 mice were chal-
enged intravenously with 1  105 viable B16-BL6 cells. For BM
onors, either (A) WT or MHC class I KO mice or (B) WT or
HC class II KO mice were vaccinated subcutaneously with B16
ysate–pulsed DCs 2 times at 4-day intervals. Four days later,
C-BM was collected. Three days after tumor challenge, recipient
ice (n 5 per group) received 5 106 intravenous T cells puriﬁed
rom nBM or DC-BM. Lungs were harvested on day 14 after tumor
hallenge. *P 	 .001; **P 	 .01 compared with HBSS-treated mice.DD indicates not detectable.
B&MT. In MHC class II KO mice,90% of DCs expressed
HC class I, and 	1% of DCs expressed MHC class
I (data not shown). To generate DC-BM, WT,
HC class I KO, and MHC class II KO mice were
accinated 2 times at 4-day intervals with B16 TP-
C. Three days after the ﬁnal vaccination, BM cells
ere harvested, and T cells were puriﬁed. As shown in
igure 6A, mice that received T cells puriﬁed from
C-BM from WT mice had a reduction in lung
etastases (100  25; P 	 .001). Mice treated with T
ells puriﬁed from DC-BM from MHC class I KO
ice had no signiﬁcant decrease in lung metastases
ompared with control mice (251 8), indicating that
HC class I–restricted T cells in BM are required for
he observed antitumor effect. In Figure 6B, mice that
eceived T cells puriﬁed from DC-BM of MHC class
I KO mice had a signiﬁcant reduction in lung metas-
ases (75  12) compared with HBSS-treated mice
187  21; P 	 .01), indicating that MHC class II–
estricted cells in BM had little effect on antitumor
mmunity against B16-BL6 tumor.
ugmented Antitumor Efficacy in Recipient Mice
y the Combination of DC-BM Transplantation
nd TP-DC Vaccination
Our next goal was to maximize the antitumor
fﬁcacy of DC-BM transplants in a therapeutic set-
ing. To this end, we investigated whether the adop-
ive transfer of tumor-speciﬁc immunity by DC-BM
ould be combined with 3 TP-DC immunizations
uring early lymphoid reconstitution. Indeed, as
hown in Figure 7, the combined treatment of
igure 7. Augmented antitumor efﬁcacy in recipient mice by the
ombination of DC-BM transplantation and TP-DC vaccination.
ALB/c mice received 2  105 viable MT-901 cells intravenously 7
ays before TBI and BMT. The nBM and TP-DC–alone groups
n  5) received BM cells from naive mice, whereas the DC-BM–
lone and DC-BMTP-DC groups (n 5) received DC-BM cells
n the BMT. TP-DC immunizations were performed as described
n Materials and Methods. Lungs were harvested 14 days after the
nal TP-DC immunization. Data are reported as the average num-
er of lung metastases  SEM. *P 	 .001 for comparison of
C-BM  TP-DC, DC-BM, and TP-DC versus nBM. **P 	 .01
or comparison of DC-BM  TP-DC versus DC-BM.C-BM plus TP-DC immunization reduced the tu-
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5or burden (45 5; P	 .001) to a greater extent than
hat afforded by the adoptive transfer of DC-BM
lone (91  11) or posttransplantation TP-DC im-
unization alone (74  17).
ISCUSSION
This study illustrated a successful transfer of tu-
or-speciﬁc immunity from a TP-DC BM donor to a
ecipient in 2 aggressive and difﬁcult-to-treat models
f metastatic cancer. In metastatic models of both a
ighly aggressive, weakly immunogenic breast cancer
Figure 1A) and a 7-day established melanoma model
Figure 1B), BM derived from a donor mouse vacci-
ated with TP-DC could transfer antitumor immu-
ity and lead to a decrease in lung metastases. Al-
hough the survival of these mice was not signiﬁcantly
ffected (data not shown), future studies will optimize
strategy for enhanced survival similar to what we
ave done previously [25].
In a myeloablative environment induced by radi-
tion, chemotherapy, or their combination, it has been
roposed that the T-cell repertoire could be skewed
uring homeostasis-driven reconstitution [43-45]. As
hown in Figure 2 and Table 1, an increase in the
umber of mature, activated T cells in the BM of
P-DC–immunized mice was detected 4 to 7 days
fter the ﬁnal immunization, and this reﬂected an
cute expansion period of activated T cells generated
y TP-DC immunization. This is also evident in Fig-
res 3 and 4, as DC-BM alone continued to proliferate
nd produce IFN- in vitro compared with nBM
lone. It has been reported that an individual activated
cell can have a large expansion potential, sufﬁcient
o repopulate the peripheral pool with a speciﬁc lim-
ted repertoire, upon T-cell activation [46-48]. The
xpansion capacity of peripheral T cells may allow
xtensive modulation of peripheral T-cell speciﬁcities;
his would confer a major role to postthymic selection
f mature peripheral T-cell repertoires. This distinct
haracteristic combined with the proliferative capacity
f DC-BM led us to theorize that the new T-cell
epertoire after BMT could be skewed in favor of
P-DC–activated T cells. Thus, the antitumor im-
une response in the DC-BM recipient was evi-
enced by a reduction in the number of lung metas-
ases (Figure 1). The results from our T cell–
epletion experiments also conﬁrmed the transfer of
ntitumor immunity by donor DC-BM to the recipi-
nt (Figure 5). It can be concluded that the antitumor
mmune response in DC-BM recipients was mediated
ainly by TP-DC activated T cells.
Our previous report demonstrated that the im-
une response elicited by TP-DC immunization in
mmunocompetent animals was dependent on both
 D4 and CD8 T cells [26]. Thus, one might as- T
30ume that the antitumor immunity successfully trans-
erred to the recipient by BM of TP-DC–immunized
ice should resemble that of the donor in which both
D4 and CD8 T cells mediate the antitumor ac-
ivity. However, it was demonstrated (Figure 6) that
he predominant effectors were MHC class I–re-
tricted CD8 T cells. Although this particular pop-
lation was not puriﬁed and examined in this study,
ur preliminary data suggest that BM does indeed
ontain a unique, antigen-speciﬁc CD8 memory T-
ell population that rapidly and speciﬁcally secretes
FN-, similar to what has been reported by others in
uman studies [19].
Most BM cells are lymphoid and myeloerythroid
recursors, which after transplantation can differenti-
te into mature cell lineages. However, there is also a
elatively small percentage of mature, differentiated
D3CD4 and CD3CD8 T cells in the BM.
oreover, it has been proposed that another subset,
amely, CD3CD4CD8 cells, might function as
egulatory T cells [49] because of their ability to
ownregulate immune responses, including inhibition
f graft-versus-host disease [50-52], CD8 T-cell
unction, and prevention of skin allograft rejection
53]. Although the origin of these CD3CD4CD8
ells is still unknown, they can be found in the BM
50-52] and in other organs [54,55]. In fact, we de-
ected an increased level of CD3CD4CD8 cells in
C-BM compared with normal BM (Figure 2). Fur-
her studies are needed to determine the biologic and
unctional implications, if any, of this unique cell type
n our model. If, indeed, such cells function as inhib-
tory cells, their selective removal from DC-BM may
rove to further enhance antitumor efﬁcacy in BMT
ecipients.
Signiﬁcant enhancement of antitumor therapeutic
fﬁcacy could be achieved in recipients of DC-BM by
he addition of TP-DC immunizations after trans-
lantation (Figure 7). We have shown in our previous
eport [33] and in this study that the repeated TP-DC
mmunizations after BMT could mediate an antitu-
or immune response in transplant recipients with
stablished tumors. The TP-DC immunization in a
ymphopenic environment could allow augmented
lonal expansion of tumor-speciﬁc lymphocytes of the
econstituting T-cell repertoire via the normal ho-
eostatic mechanisms or the “skewing” of the T-cell
egeneration, as previously proposed by Mackall et al.
34]. Other studies by Borrello et al. [56] and by
awlowska et al. [57] also demonstrated the efﬁcient
ntitumor effect by posttransplantation immunization
f the mice. In the combined DC-BM plus TP-DC
mmunization approach, the reconstituting T-cell
epertoire from the DC-BM transplant contained
mall numbers of tumor-reactive T cells. Thus, it is
onceivable that any expansion of the tumor-speciﬁc
-cell repertoire during T-cell regeneration by the
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BC-BM transplant could be further augmented by the
P-DC immunizations. Because our data do not di-
ectly prove this point, we recognize that other mech-
nisms may be involved in the ability of DC-BM T
ells to slow tumor growth, including a change in the
tate of activation, a switch to T-helper type 1 or to
emory cells, and a relative loss of a regulatory cell
ype.
Collectively, our data illustrate the successful
ransfer of antitumor efﬁcacy by the administration of
ffector T cells resident in the BM of TP-DC–immu-
ized donors and its further enhancement by TP-DC
accination of the recipient. They also raise the po-
ential for this approach in patients with advanced
ancer. In tumor-bearing patients, vaccination with
P-DC followed by autologous BMT may lead to an
ncrease of tumor-reactive CD8 T cells and an en-
anced GVT response. Although the TP-DC BM
sed in these studies was derived from healthy donors,
t is possible that patients with tumor would be inca-
able of generating an adequate immune response to
P-DC. These studies are ongoing in mice, but our
nitial studies have shown that there is no difference in
ematolymphoid reconstitution after BMT from ei-
her naive or tumor-bearing donors. Our future stud-
es will focus on the trafﬁcking and persistence of the
C-BM cells in vivo during a state of lymphopenia
nd homeostasis-driven T-cell proliferation, as well as
n the interactions between the host-tumor environ-
ent, endogenous cytokines, and the reconstituting
ffector and potential regulatory T cells of donor
rigin.
CKNOWLEDGMENTS
This work was supported by grant nos. 1 R01
A71669, 1 RO1 CA87019, 5 P01 CA59327, and 1
32 CA88784 from the National Cancer Institute/
ational Institutes of Health. W.A. and Y.K. were
qual contributors to this work.
EFERENCES
1. Mehta J, Powles R, Treleaven J, et al. Outcome of acute
leukemia relapsing after bone marrow transplantation: utility of
second transplants and adoptive immunotherapy. Bone Marrow
Transplant. 1997;19:709-719.
2. Martin TG, Gajewski JL. Allogeneic stem cell transplantation
for acute lymphocytic leukemia in adults. Hematol Oncol Clin
North Am. 2001;15:97-120.
3. Eapen M, Ramsay NK, Mertens AC, Robison LL, DeFor T,
Davies SM. Late outcomes after allogeneic bone marrow trans-
plant for aplastic anaemia. Br J Haematol. 2000;111:754-760.
4. Choi SJ, Lee KH, Kim S, et al. Prognosis value of hematopoi-
etic chimerism in patients with acute leukemia after allogeneic
bone marrow transplantation: a prospective study. Bone Marrow
Transplant. 2000;26:327-332.
B&MT5. Zang DY, Deeg HJ, Gooley T, et al. Treatment of chronic
myelomonocytic leukemia by allogeneic marrow transplanta-
tion. Br J Haematol. 2000;110:217-222.
6. Osarogiagbon RU, Defor TE, Weisdorf MA, Erice A, Weis-
dorf DJ. CMV antigenemia following bone marrow transplan-
tation: risks factors and outcomes. Biol Blood Marrow Transplant.
2000;6:280-288.
7. Fleming DR, Doukas MA, Jennings DC, Davey DD. Diagnos-
tic and clinical implications of lineage ﬁdelity in acute leukemia
patients undergoing allogeneic stem cell transplantation. Leuk
Lymphoma. 2000;36:309-313.
8. Cabrera R, Diaz-Espada F, Barrios Y, et al. Infusion of lym-
phocytes obtained from a donor immunised with the parapro-
tein idiotype as a treatment in a relapsed myeloma. Bone Marrow
Transplant. 2000;25:1105-1108.
9. Labadie J, van Tol MJ, Dijkstra NH, et al. Transfer of speciﬁc
immunity from donor to recipient of an allogeneic bone mar-
row graft: evidence for donor origin of the antibody producing
cells. Br J Haematol. 1992;82:437-444.
0. Lum LG, Seigneuret MC, Storb R. The transfer of antigen-
speciﬁc humoral immunity from marrow donors to marrow
recipients. J Clin Immunol. 1986;6:389-396.
1. Saxon A, Mitsuyasu R, Stevens R, Champlin RE, Kimata H,
Gale RP. Designed transfer of speciﬁc immune responses with
bone marrow transplantation. J Clin Invest. 1986;78:959-967.
2. Kwak LW, Taub DD, Duffey PL, et al. Transfer of myeloma
idiotype-speciﬁc immunity from an actively immunized marrow
donor. Lancet. 1995;345:1016-1020.
3. Hornung RL, Longo DL, Bowersox OC, Kwak LW. Tumor
antigen-speciﬁc immunization of bone marrow transplantation
donors as adoptive therapy against established tumor. J Natl
Cancer Inst. 1995;87:1289-1296.
4. Kwak LW, Campbell MJ, Zelenetz AD, Levy R. Transfer of
speciﬁc immunity to B-cell lymphoma with syngeneic bone
marrow in mice: a strategy for using autologous marrow as an
anti-tumor therapy. Blood. 1991;78:2768-2772.
5. Kwak LW, Pennington R, Longo DL. Active immunization of
murine allogeneic bone marrow transplant donors with B-cell
tumor-derived idiotype: a strategy for enhancing the speciﬁc
antitumor effect of marrow grafts. Blood. 1996;87:3053-3060.
6. Fontaine P, Roy-Proulx G, Knafo L, Baron C, Roy DC, Per-
reault C. Adoptive transfer of minor histocompatibility anti-
gen-speciﬁc T lymphocytes eradicates leukemia cells without
causing graft-versus-host disease. Nat Med. 2001;7:789-794.
7. Zeis M, Steinmann J, Petrela E, Hartung G, Schmitz N,
Uharek L. Transfer of idiotypic protein primed allogeneic
marrow grafts elicits potent graft-versus-myeloma effects in
mice. Bone Marrow Transplant. 2001;27:279-285.
8. Morecki S, Yacovlev E, Gelfand Y, Uzi I, Slavin S. Cell therapy
with preimmunized effector cells mismatched for minor histo-
compatibility antigens in the treatment of a murine mammary
carcinoma. J Immunother. 2001;24:114-121.
9. Feuerer M, Beckhove P, Bai L, et al. Therapy of human tumors
in NOD/SCID mice with patient-derived reactivated memory
T cells from bone marrow. Nat Med. 2001;7:452-458.
0. Peng L, Kjaergaard J, Plautz GE, Weng DE, Shu S, Cohen PA.
Helper-independent, L-selectin low CD8 T cells with broad
anti-tumor efﬁcacy are naturally sensitized during tumor pro-
gression. J Immunol. 2000;165:5738-5749.
1. To WC, Seeley BM, Barthel SW, Shu S. Therapeutic efﬁcacy
of Th1 and Th2 L-selectin–CD4 tumor-reactive T cells.
Laryngoscope. 2000;110:1648-1654.
531
22
2
2
2
2
2
2
3
3
3
3
3
3
3
3
3
3
4
4
4
4
4
4
4
4
4
4
5
5
5
5
5
W. Asavaroengchai et al.
52. Zeis M, Uharek L, Glass B, et al. Eradication of residual disease
by administration of leukemia-speciﬁc T cells after experimen-
tal allogeneic bone marrow transplantation. Exp Hematol. 1998;
26:1068-1073.
3. Cui Y, Kelleher E, Straley E, et al. Immunotherapy of estab-
lished tumors using bone marrow transplantation with antigen
gene-modiﬁed hematopoietic stem cells. Nat Med. 2003;9:952-
958.
4. Geiger J, Hutchinson R, Hohenkirk L, McKenna E, Chang A,
Mule´ JJ. Treatment of solid tumours in children with tumour-
lysate-pulsed dendritic cells. Lancet. 2000;356:1163-1165.
5. Shimizu K, Fields R, Giedlin M, Mule´ JJ. Systemic adminis-
tration of interleukin 2 enhances the therapeutic efﬁcacy of
dendritic cell-based tumor vaccines. Proc Natl Acad Sci U S A.
1999;96:2268-2273.
6. Fields RC, Shimizu K, Mule´ JJ. Murine dendritic cells pulsed
with whole lysates mediate potent antitumor immune responses
in vitro and in vivo. Proc Natl Acad Sci U S A. 1998;95:9482-
9487.
7. Herr W, Ranieri E, Olson W, Zarour H, Gesualdo L, Storkus
WJ. Mature dendritic cells pulsed with freeze-thaw cell lysates
deﬁne an effective in vitro vaccine designed to elicit EBV-
speciﬁc CD4 and CD8 T lymphocyte responses. Blood.
2000;96:1857-1864.
8. Kobayashi T, Shinohara H, Toyoda M, Iwamoto S, Tanigawa
N. Regression of lymph node metastases by immunotherapy
using autologous breast tumor-lysate pulsed dendritic cells:
report of a case. Surg Today. 2001;31:513-516.
9. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma
patients with peptide- or tumor lysate-pulsed dendritic cells.
Nat Med. 1998;4:328-332.
0. Lambert LA, Gibson GR, Maloney M, Barth RJ Jr. Equipotent
generation of protective antitumor immunity by various meth-
ods of dendritic cell loading with whole cell tumor antigens.
J Immunother. 2001;24:232-236.
1. Indrova M, Bubenik J, Simova J, et al. Therapy of HPV 16-
associated carcinoma with dendritic cell-based vaccines: in vitro
priming of the effector cell responses by DC pulsed with tu-
mour lysates and synthetic RAHYNIVTF peptide. Int J Mol
Med. 2001;7:97-100.
2. DeMatos P, Abdel-Wahab Z, Vervaert C, Hester D, Seigler H.
Pulsing of dendritic cells with lysates from either B16 mela-
noma or MCA-106 ﬁbrosarcoma yields equally effective vac-
cines against B16 tumors in mice. J Surg Oncol. 1998;68:79-91.
3. Asavaroengchai W, Kotera Y, Mule´ JJ. Tumor lysate-pulsed
dendritic cells can elicit an effective antitumor immune re-
sponse during early lymphoid recovery. Proc Natl Acad Sci U S
A. 2002;99:931-936.
4. Mackall CL, Hakim FT, Gress RE. T-cell regeneration: all
repertoires are not created equal. Immunol Today. 1997;18:245-
251.
5. Lum LG. The kinetics of immune reconstitution after human
marrow transplantation. Blood. 1987;69:369-380.
6. Mackall CL, Granger L, Sheard MA, Cepeda R, Gress RE.
T-cell regeneration after bone marrow transplantation: differ-
ential CD45 isoform expression on thymic-derived versus thy-
mic-independent progeny. Blood. 1993;82:2585-2594.
7. Bell EB, Sparshott SM, Drayson MT, Hunt SV. The origin of
T cells in permanently reconstituted old athymic nude rats.
Analysis using chromosome or allotype markers. Immunology.
1989;68:547-556.
328. Rocha BB. Population kinetics of precursors of IL 2-producing
peripheral T lymphocytes: evidence for short life expectancy,
continuous renewal, and post-thymic expansion. J Immunol.
1987;139:365-372.
9. Rocha B, Dautigny N, Pereira P. Peripheral T lymphocytes:
expansion potential and homeostatic regulation of pool sizes
and CD4/CD8 ratios in vivo. Eur J Immunol. 1989;19:905-911.
0. Drayson MT, Sparshott SM, Bell EB. Fidelity of the repertoire
in T cell reconstituted athymic nude rats. Preservation of a
deﬁcit in alloresponsiveness over one year. J Exp Med. 1989;
170:691-702.
1. Margaretten NC, Witschi H. Effects of hyperoxia on growth
characteristics of metastatic murine tumors in the lung. Cancer
Res. 1988;48:2779-2783.
2. Kim KJ, Kanellopoulos-Langevin C, Merwin RM, Sachs DH,
Asofsky R. Establishment and characterization of BALB/c lym-
phoma lines with B cell properties. J Immunol. 1979;122:549-
554.
3. Ernst B, Lee DS, Chang JM, Sprent J, Surh CD. The peptide
ligands mediating positive selection in the thymus control T
cell survival and homeostatic proliferation in the periphery.
Immunity. 1999;11:173-181.
4. Ge Q, Rao VP, Cho BK, Eisen HN, Chen J. Dependence of
lymphopenia-induced T cell proliferation on the abundance
of peptide/MHC epitopes and strength of their interaction
with T cell receptors. Proc Natl Acad Sci U S A. 2001;98:
1728-1733.
5. La Gruta NL, Driel IR, Gleeson PA. Peripheral T cell expan-
sion in lymphopenic mice results in a restricted T cell reper-
toire. Eur J Immunol. 2000;30:3380-3386.
6. Amrani A, Serra P, Yamanouchi J, et al. Expansion of the
antigenic repertoire of a single T cell receptor upon T cell
activation. J Immunol. 2001;167:655-666.
7. Surh CD, Ernst B, Lee DS, Dummer W, LeRoy E. Role of
self-major histocompatibility complex/peptide ligands in selec-
tion and maintenance of a diverse T cell repertoire. Immunol
Res. 2000;21:331-339.
8. Rocha B, Dautigny N, Pereira P. Peripheral T lymphocytes:
expansion potential and homeostatic regulation of pool sizes
and CD4/CD8 ratios in vivo. Eur J Immunol. 1989;19:905-911.
9. Zhang ZX, Young K, Zhang L. CD3CD4CD8 alpha-
beta-TCR T cell as immune regulatory cell. J Mol Med.
2001;79:419-427.
0. Abraham VS, Sachs DH, Sykes M. Mechanism of protection
from graft-versus-host disease mortality by IL-2. III. Early
reductions in donor T cell subsets and expansion of a
CD3CD4CD8 cell population. J Immunol. 1992;148:
3746-3752.
1. Palathumpat V, Dejbakhsh-Jones S, Holm B, Wang H, Liang
O, Strober S. Studies of CD4 CD8 alpha beta bone marrow
T cells with suppressor activity. J Immunol. 1992;148:373-380.
2. Palathumpat V, Dejbakhsh-Jones S, Holm B, Strober S. Dif-
ferent subsets of T cells in the adult mouse bone marrow and
spleen induce or suppress acute graft-versus-host disease. J Im-
munol. 1992;149:808-817.
3. Zhang ZX, Yang L, Young KJ, DuTemple B, Zhang L. Iden-
tiﬁcation of a previously unknown antigen-speciﬁc regulatory T
cell and its mechanism of suppression. Nat Med. 2000;6:782-
789.
4. Yamagiwa S, Sugahara S, Shimizu T, et al. The primary site of
CD4 8 B220 alphabeta T cells in lpr mice: the appendix
in normal mice. J Immunol. 1998;160:2665-2674.
55
5
Augmentation of Antitumor Immune Responses
B5. Ohteki T, Seki S, Abo T, Kumagai K. Liver is a possible site for
the proliferation of abnormal CD348 double-negative
lymphocytes in autoimmune MRL-lpr/lpr mice. J Exp Med.
1990;172:7-12.
6. Borrello I, Sotomayor EM, Rattis FM, Cooke SK, Gu L,
Levitsky HI. Sustaining the graft-versus-tumor effect through
posttransplant immunization with granulocyte-macrophageB&MTcolony-stimulating factor (GM-CSF)-producing tumor vac-
cines. Blood. 2000;95:3011-3019.
7. Pawlowska AB, Hashino S, McKenna H, Weigel BJ, Taylor
PA, Blazar BR. In vitro tumor-pulsed or in vivo Flt3 ligand-
generated dendritic cells provide protection against acute my-
elogenous leukemia in nontransplanted or syngeneic bone mar-
row-transplanted mice. Blood. 2001;97:1474-1482.533
